MACQUARIE GROUP LTD - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 237 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2022. The put-call ratio across all filers is 2.14 and the average weighting 0.1%.

Quarter-by-quarter ownership
MACQUARIE GROUP LTD ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2023$7,744,000
-22.2%
217,236
+0.7%
0.01%
-9.1%
Q2 2023$9,949,000
-73.9%
215,668
-77.3%
0.01%
-75.6%
Q1 2023$38,143,000
-27.4%
951,190
-16.1%
0.04%
-27.4%
Q4 2022$52,511,000
+13.2%
1,133,412
+1.3%
0.06%
+8.8%
Q3 2022$46,384,000
-30.0%
1,119,395
+0.8%
0.06%
-23.0%
Q2 2022$66,256,000
-15.4%
1,110,561
+3.0%
0.07%
+23.3%
Q1 2022$78,287,000
+0.7%
1,078,024
+16.6%
0.06%
-7.7%
Q4 2021$77,714,000
-7.5%
924,172
-0.8%
0.06%
-9.7%
Q3 2021$83,991,000
-5.7%
931,269
-0.3%
0.07%
-1.4%
Q2 2021$89,026,000
-23.8%
933,677
-9.0%
0.07%
-55.8%
Q1 2021$116,768,000
-27.7%
1,025,539
-12.1%
0.16%
-30.1%
Q4 2020$161,501,000
+44.2%
1,166,661
-14.4%
0.24%
+24.2%
Q3 2020$111,972,000
-6.3%
1,362,353
-10.8%
0.19%
-7.8%
Q2 2020$119,443,000
+65.7%
1,527,015
-5.9%
0.21%
+39.2%
Q1 2020$72,087,000
+19.3%
1,622,502
+14.7%
0.15%
+72.1%
Q4 2019$60,401,000
+14.2%
1,414,209
+14.4%
0.09%
-3.4%
Q3 2019$52,877,000
-65.2%
1,236,013
-48.3%
0.09%
+3.5%
Q2 2019$151,884,000
+228.4%
2,391,879
+258.7%
0.09%
+8.9%
Q1 2019$46,244,000
+198.6%
666,732
+87.2%
0.08%
+163.3%
Q4 2018$15,487,000
-22.7%
356,202
+35.7%
0.03%
-9.1%
Q3 2018$20,045,000
+2110.0%
262,577
+1935.5%
0.03%
+1550.0%
Q4 2016$907,000
-13.0%
12,900
-12.2%
0.00%0.0%
Q3 2016$1,043,000
-8.8%
14,700
-37.2%
0.00%
+100.0%
Q2 2016$1,144,000
-61.2%
23,400
-49.8%
0.00%
-83.3%
Q1 2016$2,952,000
-53.4%
46,633
-17.4%
0.01%
-53.8%
Q4 2015$6,332,000
+31.0%
56,442
+12.5%
0.01%
+30.0%
Q3 2015$4,833,000
-17.7%
50,184
-12.5%
0.01%
-16.7%
Q2 2015$5,871,000
+226.0%
57,337
+97.7%
0.01%
+200.0%
Q1 2015$1,801,000
+315.9%
29,000
+194.1%
0.00%
+300.0%
Q4 2014$433,000
-22.4%
9,8620.0%0.00%0.0%
Q3 2014$558,000
+26.0%
9,8620.0%0.00%0.0%
Q2 2014$443,000
-8.1%
9,8620.0%0.00%0.0%
Q1 2014$482,0009,8620.00%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q1 2022
NameSharesValueWeighting ↓
First Light Asset Management, LLC 441,159$39,788,0002.62%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 103,100$9,286,0002.24%
Rock Springs Capital Management LP 801,109$72,252,0001.52%
Avidity Partners Management LP 455,000$41,036,0000.91%
Motley Fool Asset Management LLC 134,357$12,118,0000.79%
FEDERATED HERMES, INC. 3,987,032$359,590,0000.68%
EMERALD ADVISERS, LLC 196,124$17,688,0000.64%
Ergoteles LLC 128,100$11,553,0000.42%
Tekla Capital Management LLC 140,726$12,692,0000.41%
Beck Bode, LLC 14,990$1,352,0000.38%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders